Dr Gerard Costello
Gerard is an expert in R&D and Product Development. He is the former Global Portfolio Manager in the Cancer and Infection Research Area at Astra Zeneca. He was the Project Leader for the following innovative drugs: ZD9331 Thymidylate synthase inhibitor and ‘Iressa’ gefitinib, ZD1839 - EGF Receptor Tyrosine Kinase Inhibitor - launched worldwide for Non-small Cell Lung Cancer, the first of Zeneca’s signal transduction approaches, VEGFR project, from which Recentin (cediranib, AZD2171) and Zactima (vandetanib, ZD6474) subsequently emerged. Gerard is a graduate of Oxford University, UK - Chemistry with PhD from the ETH-Zurich, Switzerland.